A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

NCT02155322 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC